IDO1 and in situ carcinoma: The proportion of CD3−CD56hiCD16lo NK cells (representing approximately 10% NK cells) in PBMCs from CIS patients was associated with greater IDO1 mRNA levels (Supplementary table 2) but is of unknown meaning as this relationship was not detected for the higher IDO1 levels in cells from MS patients (Figure 1).